A safe, well tolerated, flexible non-drug therapy1,2
No patients in the ACT1 or ACT2 studies experienced adverse events typically associated with many pharmacologics.1,2
- No dizziness, somnolence, nausea, or vomiting1,2
- No gammaCore (nVNS)—drug interactions were observed1
In ACT1, the most common adverse device-related events were mild and transient and occurred primarily during administration1,2
In ACT2, no adverse device-related events were observed in ≥5% of patients in any treatment group1
References: 1. gammaCore Instructions for Use. Basking Ridge, NJ: electroCore, LLC; 2017. 2. Silberstein SD, Mechtler LL, Kudrow DB, et al; ACT1 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56(8):1317-1332.